1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

US FDA Asked To Tighten China Risk Control By Legislators As Markup Looms

 
• By Brian Yang

The proposed US BIOSECURE Act is heading to a full committee vote amid heightening tensions, underscored by new US Congressional Oversight Committee letters to the FDA asking it to examine national security threats posed by Chinese 'biotechs of concern.'

US-China flag wall
US Congressional Oversight Committee sends letter to FDA on China risks, BIOSECURE vote looms • Source: Shutterstock

As the US House of Representatives' influential Oversight and Accountability Committee chairman James Comer (R-KY) prepares for a markup of legislation aimed at decoupling the biopharma industry from Chinese manufacturers and developers, he is also pressing the US Food and Drug Administration on a separate track.

In a 6 May letter to FDA, Comer warned the committee sees it as “increasingly clear that the CCP [Chinese Communist Party] seeks to weaponize genomic and medical data and use strategies like its

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America